IL6 and cancer: Neopterin and IL‐6 appear to be suitable primarily as markers for therapeutic efficacy or early‐stage cancer diagnosis, as suggested by their elevation in oral premalignant conditions and stage I of SCCHN (Juretić et al. 2013; Oshin et al. 2024).